2017 ACVIM Forum Research Abstract Program

In this unmasked study, 2% MZP was applied topically to the inner pinna of five healthy adult intact female cats and two intact female cats with chronic kidney disease (CKD) (serum creatinine 1.7 mg/dL and 1.5 mg/dL; urine specific gravity 1.023 and 1.037 respectively) daily for 28 consecutive days at 5 mg/kg. Cats ranged in age from 1.4 to 3.2 years. 2% MZP volume was split equally between ears at each administration. Behavioral observations were conducted twice daily throughout the study and scored on interaction, activity, vocalization, and tremors. Physical examination, ECG, and doppler blood pressure were conducted on study days À5, 13 and 27. Scanning echocardiogram and abdominal ultrasound were conducted on study days À6 and 26. Hematology, and serum chemistry were conducted on study days À6, 13, and 27. Body weights were measured on study days À5, À1, 6, 13, 20 and 27. Body weight, blood pressure, and serum ALT were compared between time points using a Wilcoxon Signed Rank Test for paired samples. Sum of pre-dose mean behavior scores were compared to mean behavior scores at Day 27 using a Wilcoxon Signed Rank Test for paired samples. Statistical significance was set at P < 0.05 for all tests.